Breastfeeding and breast cancer risk by receptor status-a systematic review and meta-analysis

Annals of Oncology

Volumn 26, Issue 12, 2015, Pages 2398-2407

  Islami, F ^a,b   Liu, Y ^c   Jemal, A ^a   Zhou, J ^b   Weiderpass, E ^d,e,f,g   Colditz, G ^c,h   Boffetta, P ^b   Weiss, M ⁱ  

^a AMERICAN CANCER SOCIETY   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d KAROLINSKA INSTITUTE   (Sweden)

^e UNIVERSITY OF TROMSØ   (Norway)

^f CANCER REGISTRY OF NORWAY   (Norway)

^g FOLKHÄLSAN RESEARCH CENTER   (Finland)

^h Washington University in St Louis School of Medicine   (United States)

ⁱ Breastcancerorg breasthealthorg   (United States)

Author keywords

Breast cancer; Breastfeeding; Estrogen receptor; HER2 receptor; Meta analysis; Progesterone receptor

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; ERBB2 PROTEIN, HUMAN;

ARTICLE; BREAST CANCER; BREAST FEEDING; CANCER INCIDENCE; CANCER RISK; CASE CONTROL STUDY; COHORT ANALYSIS; HUMAN; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SYSTEMATIC REVIEW; TRIPLE NEGATIVE BREAST CANCER; BIOSYNTHESIS; BREAST TUMOR; FEMALE; META ANALYSIS; METABOLISM; TRENDS;

BREAST FEEDING; BREAST NEOPLASMS; CASE-CONTROL STUDIES; COHORT STUDIES; FEMALE; HUMANS; PROSPECTIVE STUDIES; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RISK FACTORS;

EID: 84949974044     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdv379     Document Type: Article

References (81)

1. Jemal A, Bray F, Center MM et al. Global cancer statistics. CA Cancer J Clin. 2011; 61: 69-90.
2. DeSantis C, Ma J, Bryan L, Jemal A. Breast cancer statistics, 2013. CA Cancer J Clin 2014; 64: 52-62.
3. Bradbury AR, Olopade OI. Genetic susceptibility to breast cancer. Rev Endocr Metab Disord 2007; 8: 255-267.
4. Kim H, Choi DH. Distribution of BRCA1 and BRCA2 mutations in Asian patients with breast cancer. J Breast Cancer 2013; 16: 357-365.
5. Colditz GA, Bohlke K. Priorities for the primary prevention of breast cancer. CA Cancer J Clin 2014; 64: 186-194.
6. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and breastfeeding: collaborative reanalysis of individual data from 47 epidemiological studies in 30 countries, including 50302 women with breast cancer and 96973 women without the disease. Lancet 2002; 360: 187-195.
7. Anothaisintawee T, Wiratkapun C, Lerdsitthichai P et al. Risk factors of breast cancer: a systematic review and meta-analysis. Asia Pac J Public Health 2013; 25: 368-387.
8. Shinde SS, Forman MR, Kuerer HM et al. Higher parity and shorter breastfeeding duration: association with triple-negative phenotype of breast cancer. Cancer 2010; 116: 4933-4943.
9. Gaudet MM, Press MF, Haile RW et al. Risk factors by molecular subtypes of breast cancer across a population-based study of women 56 years or younger. Breast Cancer Res Treat 2011; 130: 587-597.
10. Li CI, Beaber EF, Tang MT et al. Reproductive factors and risk of estrogen receptor positive, triple-negative, and HER2-neu overexpressing breast cancer among women 20-44 years of age. Breast Cancer Res Treat 2013; 137: 579-587.
11. Phipps AI, Malone KE, Porter PL et al. Reproductive and hormonal risk factors for postmenopausal luminal, HER-2-overexpressing, and triple-negative breast cancer. Cancer 2008; 113: 1521-1526.
12. Redondo CM, Gago-Dominguez M, Ponte SM et al. Breast feeding, parity and breast cancer subtypes in a Spanish cohort. PLoS One 2012; 7: e40543.
13. Tamimi RM, Colditz GA, Hazra A et al. Traditional breast cancer risk factors in relation to molecular subtypes of breast cancer. Breast Cancer Res Treat 2012; 131: 159-167.
14. Anderson KN, Schwab RB, Martinez ME. Reproductive risk factors and breast cancer subtypes: a review of the literature. Breast Cancer Res Treat 2014; 144: 1-10.
15. Howlader N, Altekruse SF, Li CI et al. US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. J Natl Cancer Inst 2014; 106: pii: dju055.
16. Ritte R, Tikk K, Lukanova A et al. Reproductive factors and risk of hormone receptor positive and negative breast cancer: a cohort study. BMC Cancer 2013; 13: 584.
17. Sheridan W, Scott T, Caroline S et al. Breast cancer in young women: have the prognostic implications of breast cancer subtypes changed over time? Breast Cancer Res Treat 2014; 147: 617-629.
18. Gluz O, Liedtke C, Gottschalk N et al. Triple-negative breast cancer-current status and future directions. Ann Oncol 2009; 20: 1913-1927.
19. Brinton LA, Figueroa JD, Awuah B et al. Breast cancer in Sub-Saharan Africa: opportunities for prevention. Breast Cancer Res Treat 2014; 144: 467-478.
20. Ma H, Bernstein L, Pike MC, Ursin G. Reproductive factors and breast cancer risk according to joint estrogen and progesterone receptor status: a meta-analysis of epidemiological studies. Breast Cancer Res 2006; 8: R43.
21. Stroup DF, Berlin JA, Morton SC et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000; 283: 2008-2012.
22. Yoo KY, Tajima K, Miura S et al. Breast cancer risk factors according to combined estrogen and progesterone receptor status: a case-control analysis. Am J Epidemiol 1997; 146: 307-314.
23. Chung S, Park SK, Sung H et al. Association between chronological change of reproductive factors and breast cancer risk defined by hormone receptor status: results from the Seoul Breast Cancer Study. Breast Cancer Res Treat 2013; 140: 557-565.
24. Cummings SR, Lee JS, Lui LY et al. Sex hormones, risk factors, and risk of estrogen receptor-positive breast cancer in older women: a long-term prospective study. Cancer Epidemiol Biomarkers Prev 2005; 14: 1047-1051.
25. Rusiecki JA, Holford TR, Zahm SH, Zheng T. Breast cancer risk factors according to joint estrogen receptor and progesterone receptor status. Cancer Detect Prev 2005; 29: 419-426.
26. Chlebowski RT, Anderson GL, Lane DS et al. Predicting risk of breast cancer in postmenopausal women by hormone receptor status. J Natl Cancer Inst 2007; 99: 1695-1705.
27. Ma H, Henderson KD, Sullivan-Halley J et al. Pregnancy-related factors and the risk of breast carcinoma in situ and invasive breast cancer among postmenopausal women in the California Teachers Study cohort. Breast Cancer Res 2010; 12: R35.
28. Palmer JR, Boggs DA, Wise LA et al. Parity and lactation in relation to estrogen receptor negative breast cancer in African American women. Cancer Epidemiol Biomarkers Prev 2011; 20: 1883-1891.
29. Warner ET, Colditz GA, Palmer JR et al. Reproductive factors and risk of premenopausal breast cancer by age at diagnosis: are there differences before and after age 40? Breast Cancer Res Treat 2013; 142: 165-175.
30. Butt S, Borgquist S, Anagnostaki L et al. Breastfeeding in relation to risk of different breast cancer characteristics. BMC Res Notes 2014; 7: 216.
31. Horn J, Opdahl S, Engstrom MJ et al. Reproductive history and the risk of molecular breast cancer subtypes in a prospective study of Norwegian women. Cancer Causes Control 2014; 25: 881-889.
32. Hildreth NG, Kelsey JL, Eisenfeld AJ et al. Differences in breast cancer risk factors according to the estrogen receptor level of the tumor. J Natl Cancer Inst 1983; 70: 1027-1031.
33. McTiernan A, Thomas DB, Johnson LK, Roseman D. Risk factors for estrogen receptor-rich and estrogen receptor-poor breast cancers. J Natl Cancer Inst 1986; 77: 849-854.
34. Cooper JA, Rohan TE, Cant EL et al. Risk factors for breast cancer by oestrogen receptor status: a population-based case-control study. Br J Cancer 1989; 59: 119-125.
35. Britton JA, Gammon MD, Schoenberg JB et al. Risk of breast cancer classified by joint estrogen receptor and progesterone receptor status among women 20-44 years of age. Am J Epidemiol 2002; 156: 507-516.
36. Cotterchio M, Kreiger N, Theis B et al. Hormonal factors and the risk of breast cancer according to estrogen- and progesterone-receptor subgroup. Cancer Epidemiol Biomarkers Prev 2003; 12: 1053-1060.
37. Nichols HB, Trentham-Dietz A, Love RR et al. Differences in breast cancer risk factors by tumor marker subtypes among premenopausal Vietnamese and Chinese women. Cancer Epidemiol Biomarkers Prev 2005; 14: 41-47.
38. Ursin G, Bernstein L, Lord SJ et al. Reproductive factors and subtypes of breast cancer defined by hormone receptor and histology. Br J Cancer 2005; 93: 364-371.
39. Millikan RC, Newman B, Tse CK et al. Epidemiology of basal-like breast cancer. Breast Cancer Res Treat 2008; 109: 123-139.
40. Sweeney C, Baumgartner KB, Byers T et al. Reproductive history in relation to breast cancer risk among Hispanic and non-Hispanic white women. Cancer Causes Control 2008; 19: 391-401.
41. Dey S, Boffetta P, Mathews A et al. Risk factors according to estrogen receptor status of breast cancer patients in Trivandrum, South India. Int J Cancer 2009; 125: 1663-1670.
42. Dolle JM, Daling JR, White E et al. Risk factors for triple-negative breast cancer in women under the age of 45 years. Cancer Epidemiol Biomarkers Prev 2009; 18: 1157-1166.
43. Xing P, Li J, Jin F. A case-control study of reproductive factors associated with subtypes of breast cancer in Northeast China. Med Oncol 2010; 27: 926-931.
44. Bao PP, Shu XO, Gao YT et al. Association of hormone-related characteristics and breast cancer risk by estrogen receptor/progesterone receptor status in the shanghai breast cancer study. Am J Epidemiol 2011; 174: 661-671.
45. Islam T, Matsuo K, Ito H et al. Reproductive and hormonal risk factors for luminal, HER2-overexpressing, and triple-negative breast cancer in Japanese women. Ann Oncol 2012; 23: 2435-2441.
46. Kawai M, Kakugawa Y, Nishino Y et al. Reproductive factors and breast cancer risk in relation to hormone receptor and menopausal status in Japanese women. Cancer Sci 2012; 103: 1861-1870.
47. Ambrosone CB, Zirpoli G, Ruszczyk M et al. Parity and breastfeeding among African-American women: differential effects on breast cancer risk by estrogen receptor status in the Women's Circle of Health Study. Cancer Causes Control 2014; 25: 259-265.
48. Work ME, John EM, Andrulis IL et al. Reproductive risk factors and oestrogen/ progesterone receptor-negative breast cancer in the Breast Cancer Family Registry. Br J Cancer 2014; 110: 1367-1377.
49. Phipps AI, Chlebowski RT, Prentice R et al. Reproductive history and oral contraceptive use in relation to risk of triple-negative breast cancer. J Natl Cancer Inst 2011; 103: 470-477.
50. Trivers KF, Lund MJ, Porter PL et al. The epidemiology of triple-negative breast cancer, including race. Cancer Causes Control 2009; 20: 1071-1082.
51. Ma H, Wang Y, Sullivan-Halley J et al. Use of four biomarkers to evaluate the risk of breast cancer subtypes in the women's contraceptive and reproductive experiences study. Cancer Res 2010; 70: 575-587.
52. Palmer JR, Viscidi E, Troester MA et al. Parity, lactation, and breast cancer subtypes in African American women: results from the AMBER Consortium. J Natl Cancer Inst 2014; 106: pii: dju237.
53. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin.Trials 1986; 7: 177-188.
54. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557-560.
55. Begg CB, Berlin JA. Publication bias and dissemination of clinical research. J Natl Cancer Inst 1989; 81: 107-115.
56. Egger M, Smith GD. Bias in location and selection of studies. BMJ 1998; 316: 61-66.
57. Press DJ, Pharoah P. Risk factors for breast cancer: a reanalysis of two casecontrol studies from 1926 and 1931. Epidemiology 2010; 21: 566-572.
58. Pan H, He Z, Ling L et al. Reproductive factors and breast cancer risk among BRCA1 or BRCA2 mutation carriers: results from ten studies. Cancer Epidemiol 2014; 38: 1-8.
59. Friebel TM, Domchek SM, Rebbeck TR. Modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers: systematic review and meta-analysis. J Natl Cancer Inst 2014; 106: dju091.
60. Lakhani SR, Van De Vijver MJ, Jacquemier J et al. The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J Clin Oncol 2002; 20: 2310-2318.
61. McNamara KM, Yoda T, Takagi K et al. Androgen receptor in triple negative breast cancer. J Steroid Biochem Mol Biol 2013; 133: 66-76.
62. Schmadeka R, Harmon BE, Singh M. Triple-negative breast carcinoma: current and emerging concepts. Am J Clin Pathol 2014; 141: 462-477.
63. Mayer IA, Abramson VG, Lehmann BD, Pietenpol JA. New strategies for triple-negative breast cancer-deciphering the heterogeneity. Clin Cancer Res 2014; 20: 782-790.
64. Kobayashi S, Sugiura H, Ando Y et al. Reproductive history and breast cancer risk. Breast Cancer 2012; 19: 302-308.
65. Tamimi RM, Byrne C, Colditz GA, Hankinson SE. Endogenous hormone levels, mammographic density, and subsequent risk of breast cancer in postmenopausal women. J Natl Cancer Inst 2007; 99: 1178-1187.
66. Ramon YCT, Chirivella I, Miranda J et al. Mammographic density and breast cancer in women from high risk families. Breast Cancer Res 2015; 17: 93.
67. Maskarinec G, Nakamura KL, Woolcott CG et al. Mammographic density and breast cancer risk by family history in women of white and Asian ancestry. Cancer Causes Control 2015; 26: 621-626.
68. Vachon CM, Pankratz VS, Scott CG et al. The contributions of breast density and common genetic variation to breast cancer risk. J Natl Cancer Inst 2015; 107: pii: dju397.
69. Riza E, dos Santos Silva I, De Stavola B et al. Correlates of high-density mammographic parenchymal patterns by menopausal status in a rural population in Northern Greece. Eur J Cancer 2005; 41: 590-600.
70. Ursin G, Sun CL, Koh WP et al. Associations between soy, diet, reproductive factors, and mammographic density in Singapore Chinese women. Nutr Cancer 2006; 56: 128-135.
71. Sung J, Song YM, Stone J et al. Reproductive factors associated with mammographic density: a Korean co-twin control study. Breast Cancer Res Treat 2011; 128: 567-572.
72. Ahmadinejad N, Movahedinia S, Movahedinia S et al. Distribution of breast density in Iranian women and its association with breast cancer risk factors. Iran Red Crescent Med J 2013; 15: e16615.
73. Crew KD, Campbell J, Reynolds D et al. Mammographic density and serum 25-hydroxyvitamin D levels. Nutr Metab (Lond) 2014; 11: 18.
74. Yang Y, Liu J, Gu R et al. Influence of factors on mammographic density in premenopausal Chinese women. Eur J Cancer Prev 2015 June 11 [epub ahead of print], doi: 10.1097/CEJ.0000000000000177.
75. den Hollander P, Savage MI, Brown PH. Targeted therapy for breast cancer prevention. Front Oncol 2013; 3: 250.
76. Spencer BS, Grassley JS. African American women and breastfeeding: an integrative literature review. Health Care Women Int 2013; 34: 607-625.
77. Bartick MC, Stuebe AM, Schwarz EB et al. Cost analysis of maternal disease associated with suboptimal breastfeeding. Obstet Gynecol 2013; 122: 111-119.
78. Sharma AJ, Dee DL, Harden SM. Adherence to breastfeeding guidelines and maternal weight 6 years after delivery. Pediatrics 2014; 134(Suppl 1): S42-S49.
79. Ip S, Chung M, Raman G et al. Breastfeeding and maternal and infant health outcomes in developed countries. Evid Rep Technol Assess (Full Rep) 2007; 153: 1-186.
80. Huttly SR, Barros FC, Victora CG et al. Do mothers overestimate breast feeding duration? An example of recall bias from a study in southern Brazil. Am J Epidemiol 1990; 132: 572-575.
81. Lee H, Li JY, Fan JH et al. Risk factors for breast cancer among Chinese women: a 10-year nationwide multicenter cross-sectional study. J Epidemiol 2014; 24: 67-76.